teva logo 88.
(photo credit: )
X
Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before.
Nevertheless, traditional business models are no longer sustainable and high-quality publications,
like ours, are being forced to look for new ways to keep going. Unlike many other news organizations,
we have not put up a paywall. We want to keep our journalism open
and accessible and be able to keep providing you with news
and analyses from the frontlines of Israel, the Middle East and the Jewish World.
As one of our loyal readers, we ask you to be our partner.
For $5 a month you will receive access to the following:
- A user experience almost completely free of ads
- Access to our Premium Section
- Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
- A brand new ePaper featuring the daily newspaper as it appears in print in Israel
Help us grow and continue telling Israel’s story to the world.
Thank you,
Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief
UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH
Show me later
Teva Pharmeceutical Industries said Sunday it expects to close its acquisition of Ivax Corporation by January 12.
Teva agreed to buy Ivax in July for $7.4 billion, the largest ever acquisition by an Israeli company.
The companies said they have signed a consent order for submission to the US Federal Trade Commision (FTC) which is "the last remaining regulatory condition to the consummation of the transaction."
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>